Loading
This review explains how mucinous ovarian cancer differs from other ovarian cancers, why metastases from the bowel must be excluded, and how surgery, fertility preservation and chemotherapy choices are made in a disease with little trial evidence.
Review covering the epidemiology, pathology and immunohistochemical distinction of primary mucinous ovarian carcinoma from metastatic gastrointestinal tumours, expansile versus infiltrative patterns, molecular features, surgical staging and fertility-sparing surgery, the role of appendicectomy, adjuvant chemotherapy including gastrointestinal-type regimens, and management of advanced disease.
The mucinous ovarian cancer page's emphasis on excluding a gastrointestinal primary, omitting chemotherapy for early expansile tumours, and considering gastrointestinal-type regimens follows this review.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/